{
    "id": "46784047",
    "text": "Lemborexant, sold under the brand name Dayvigo, is a medication for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf Lemborexant was approved in the United States for use by adults with insomnia in December 2019. ==Medical uses== Lemborexant is used in the treatment of insomnia. ==Pharmacology== ===Pharmacodynamics=== Lemborexant is a dual antagonist of the orexin OX1 and OX2 receptors. ===Pharmacokinetics=== The time to peak levels of lemborexant is 1 to 3 hours. A high-fat and high- calorie meal has been found to delay the time to peak levels by 2 hours. Its plasma protein binding in vitro is 94%. Lemborexant is metabolized primarily by CYP3A4 and to a lesser extent by CYP3A5. The elimination half-life of lemborexant is 17 to 19 hours. The medication is excreted in feces (57%) and to a lesser extent urine (29%). ==History== In June 2016, Eisai initiated Phase III clinical trials in the United States, France, Germany, Italy, Japan, Poland, Spain and the UK. In December 2019, lemborexant was approved for use in the United States based on results from the SUNRISE 1 and SUNRISE 2 Phase III clinical trials. ==Society and culture== ===Generic names=== Lemborexant is the generic name of the drug and its . ===Brand names=== Lemborexant is sold under the brand name Dayvigo. ==References== ==Further reading== * * * ==External links== * Category:Carboxamides Category:Cyclopropanes Category:Fluoroarenes Category:Hypnotics Category:Japanese inventions Category:Orexin antagonists Category:Organofluorides Category:Pyrimidines Category:Pyridines ",
    "title": "Lemborexant"
}